Roku, Inc. v. Universal Electronics, Inc., Appeal No. 2022-1058 (Fed. Cir. Mar. 31, 2023)
In this week’s Case of the Week, the Federal Circuit affirmed the U.S. Patent Trial and Appeal Board’s (PTAB’s) final written...more
4/4/2023
/ Claim Construction ,
Final Written Decisions ,
Food and Drug Administration (FDA) ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Inventions ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents
Apple Inc. v. Vidal, Appeal No. 2022-1249 (Fed. Cir. Mar. 13, 2023)
In our Case of the Week, the Federal Circuit allowed Apple’s challenge to the Patent Trial and Appeal Board’s (“PTAB”) Fintiv rules to proceed, at least...more
3/21/2023
/ Administrative Procedure Act ,
Appeals ,
Claim Construction ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Notice and Comment ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Prior Art ,
Remand ,
Rulemaking Process ,
USPTO
Regents of the University of Minnesota v. Gilead Sciences, Inc., Appeal No. 21-2168 (Fed. Cir. Mar. 6, 2023)
The Federal Circuit’s only precedential patent opinion this week focuses on the written description requirement...more
3/14/2023
/ Administrative Procedure Act ,
Anticipation ,
Appeals ,
Inter Partes Review (IPR) Proceeding ,
Patent Applications ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Sovereign Immunity ,
USPTO ,
Written Descriptions
CyWee Grp. Ltd. v. Google LLC, Appeal No. 20-1565 (Fed. Cir. Feb. 8, 2023)
In its only precedential patent case this week, the Federal Circuit addressed last gasp efforts by CyWee to salvage its IPR losses to Google. The...more
American National Manufacturing Inc. v. Sleep Number Corporation, Appeal Nos. 2021-1321, -1323, -1379, -1382 (Fed. Cir. Nov. 14, 2022) -
In an appeal from inter partes review proceedings before the Patent Trial and Appeal...more
Provisur Technologies, Inc. v. Weber, Inc., Appeal Nos. 2021-1942, -1975 (Fed. Cir. Sept. 27, 2022) -
In this week’s Case of the Week, the Federal Circuit reviewed an IPR decision and addressed the Patent Trial and Appeal...more
10/4/2022
/ Administrative Procedure Act ,
Alice/Mayo ,
Appeals ,
Claim Limitations ,
Federal Rules of Evidence ,
Inter Partes Review (IPR) Proceeding ,
Motion to Exclude ,
Patent Applications ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Prior Art ,
Reversal ,
Vacated
Best Medical International, Inc. v. Elekta Inc., Appeal Nos. 2021-2099, -2100 (Fed. Cir. Aug. 26, 2022) -
In this week’s Case of the Week, the Federal Circuit addressed issues of jurisdiction where a challenged claim was...more
8/30/2022
/ Alice/Mayo ,
Appeals ,
Ex Partes Reexamination ,
Inter Partes Review (IPR) Proceeding ,
Jurisdiction ,
Obviousness ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art ,
Section 101
This week, we provide extensive write-ups about two consequential decisions issued by the United States Court of Appeals for the Federal Circuit concerning two procedural issues under the America Invents Act (“AIA”), both...more
8/23/2022
/ America Invents Act ,
Appeals ,
Declaratory Relief ,
Inter Partes Review (IPR) Proceeding ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
SCOTUS ,
Thryv Inc v Click-To-Call Technologies LP ,
United States v Arthrex Inc ,
USPTO
LG Electronics Inc. v. Immervision, Inc., Appeal Nos. 2021-2037, -2038 (Fed. Cir. 2022)
In this week’s Case of the Week, the Federal Circuit considered how to treat a prior art reference in which the alleged teaching of...more
Pavo Solutions LLC v. Kingston Technology Company, Inc., Appeal No. 2021-1834 (Fed. Cir. June 3, 2022) -
In our Case of the Week, the Court of Appeals for the Federal Circuit affirmed a $7M compensatory damages award and,...more
Hunting Titan, Inc. v. DynaEnergetics Europe GMBH, Appeal Nos. 2020-2163, -2191 (Fed. Cir. March 24, 2022) -
In a notable review of the USPTO’s new Precedential Opinions Panel, the Federal Circuit discussed the...more
3/29/2022
/ Claim Construction ,
Indefiniteness ,
Inter Partes Review (IPR) Proceeding ,
Means-Plus-Function ,
Motion to Amend ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Precedential Opinion ,
Remand ,
USPTO
In re: Volkswagen Group of America, Inc. and In re: Hyundai Motor America, Appeal Nos. 2022-108, -109 (Fed. Cir. Mar. 9, 2022) -
In the most recent of multiple mandamus rulings issued by the Federal Circuit in relation to...more
3/15/2022
/ Appeals ,
Claim Construction ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Vacated ,
Venue ,
Writ of Mandamus ,
Written Descriptions
Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., Appeal No. 2020-2106 (Fed. Cir. Feb. 10, 2022) -
In our Case of the Week, the Court of Appeals for the Federal Circuit, in both the majority opinion and...more
2/15/2022
/ Appeals ,
En Banc Review ,
Inter Partes Review (IPR) Proceeding ,
IP License ,
Motion To Seal ,
Obviousness ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Third-Party ,
Vacated
The Federal Circuit issued numerous precedential opinions last week, two of which answered long simmering questions about inter partes reviews (IPRs). Below we discuss a case addressing whether admissions of prior art in the...more
2/8/2022
/ Abstract Ideas ,
Appeals ,
Claim Construction ,
Damages ,
Estoppel ,
Inter Partes Review (IPR) Proceeding ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Preliminary Injunctions ,
Prior Art ,
Remand ,
Settlement Agreements
University of Strathclyde v. Clear-Vu Lighting LLC, Appeal No. 2021-2243 (Fed. Cir. Nov. 4, 2021) -
In this week’s Case of the Week, the Federal Circuit reversed an inter partes review decision finding claims directed to...more
11/9/2021
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Dismissals ,
Improper Venue ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Prior Art
Kannuu Pty Ltd. v. Samsung Electronics Co., Appeal No. 2021-1638 (Fed. Cir. Oct. 7, 2021) -
In our Case of the Week, the Federal Circuit addressed whether a forum selection clause in an NDA may prohibit a party from...more
10/12/2021
/ Appeals ,
Claim Construction ,
Design Patent ,
Inter Partes Review (IPR) Proceeding ,
Non-Disclosure Agreement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent Validity ,
Patents ,
Section 101 ,
Subject Matter Jurisdiction
Teva Pharms. Int’l GmbH v. Eli Lilly and Co., Appeal Nos. 2020-1747, -1748, -1750 (Fed. Cir. Aug. 16, 2021) -
Eli Lilly and Co. v. Teva Pharms. Int’l GmbH, Appeal Nos. 2020-1876, -1877, -1878 (Fed. Cir. Aug. 16, 2021)...more
Trimble Inc. v. PerDiemCo LLC, Appeal No. 2019-2164 (Fed. Cir. May 12, 2021) -
In this week’s Case of the Week, the Federal Circuit revisited its decision in Red Wing Shoe Co. v. Hockerson-Halberstadt, Inc., 148 F.3d 1355...more
5/18/2021
/ Abstract Ideas ,
Appeals ,
Claim Construction ,
Covered Business Method Proceedings ,
Declaratory Judgments ,
Inter Partes Review (IPR) Proceeding ,
Non-Practicing Entities ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Personal Jurisdiction ,
Summary Judgment
Wi-LAN Inc. v. Sharp Electronics Corporation, Appeal Nos. 2020-1041, -1043 (Fed. Cir. Apr. 6, 2021) -
In this week’s Case of the Week, the Federal Circuit addressed issues of claim construction and various issues...more
4/13/2021
/ Apple ,
Article III ,
Business Records Exception ,
Claim Construction ,
Copyright Infringement ,
Federal Rules of Evidence ,
Inter Partes Review (IPR) Proceeding ,
Manufacturers ,
Qualcomm ,
Settlement ,
Source Code ,
Standing ,
Third-Party
Uniloc 2017 LLC v. Facebook Inc., Appeal Nos. 2019-1688, -1689 (Fed. Cir. Mar. 9, 2021) In this week’s Case of the Week, Uniloc appealed from two consolidated IPR decisions finding multiple claims unpatentable as obvious....more
3/17/2021
/ § 314(d) ,
§ 315(b) ,
Appeals ,
Claim Construction ,
Facebook ,
Inter Partes Review (IPR) Proceeding ,
Mandamus Petitions ,
Non-Appealable Decisions ,
Noninfringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Summary Judgment
SynQor, Inc. v. Vicor Corp., Appeal No. 2019-1704 (Fed. Cir. Feb. 22, 2021) -
In this week’s Case of the Week, the Federal Circuit held that common law collateral estoppel could arise from a factual determination made in...more
Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir. Feb. 11, 2021) -
In this week’s Case of the Week, the Federal Circuit affirmed a district court’s JMOL ruling that asserted claims of two related pharmaceutical patents...more
2/17/2021
/ Appeals ,
Indefiniteness ,
Inter Partes Review (IPR) Proceeding ,
JMOL ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patent-Eligible Subject Matter ,
Patents ,
Pharmaceutical Patents ,
Summary Judgment
General Electric Co. v. Raytheon Techs. Corp., Appeal No. 2019-1319 (Fed. Cir. Dec. 23, 2020) -
In one of two precedential opinions this week, the Federal Circuit established new precedent concerning what it takes for a...more
C.R. Bard Inc. v. AngioDynamics, Inc., Appeal No. 2019-1756, -1934 (Fed. Cir. Nov. 10, 2020) -
Our Case of the Week is one of two cases decided this week in which the Federal Circuit finds that a district court jumped the...more
11/17/2020
/ Appeals ,
Appellate Courts ,
Claim Construction ,
Discovery ,
Dismissals ,
Equitable Estoppel ,
Genuine Issue of Material Fact ,
Inter Partes Review (IPR) Proceeding ,
Inventors ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Petition for Writ of Certiorari ,
Pharmaceutical Patents ,
Summary Judgment
Immunex Corp. v. Sanofi-Aventis U.S. LLC, Appeal Nos. 2019-1749, -1777 (Fed. Cir. Oct. 13, 2020) -
In our Case of the Week, the Federal Circuit addressed the construction of the term “human antibodies.” In doing so, the...more